Claus Zippel, Christina Antke, Yuriko Mori, Antje Sombetzki, Gerald Antoch, Frederik L Giesel
Background: Imaging devices such as PET/CT are becoming increasingly important in view of the growing range of innovative nuclear medicine diagnostic procedures. Since the procurement and commissioning as well as the ongoing operation of imaging devices leads to comparatively high costs, it is of great interest for clinics and practices to know the number of scans from which the (planned) device operation leads to a profit. In the following, we will introduce the breakeven point analysis and present a calculation tool that users in nuclear medicine clinics and practices can use in everyday operations using PET/CT as an example.
Methods: In the breakeven point analysis, the intersection point is determined from which the organisation- or device-specific revenues exceed the total costs incurred for personnel, material resources, etc. For this purpose, the fixed and variable (planned) cost components for the procurement and operation of the device must be prepared on the cost side and the respective device-related (planned) revenue structure on the revenue side.
Results: The authors present the break-even analysis method with the data processing required for this using the example of the planned procurement or ongoing operation of a PET/CT. In addition, a calculation tool was developed, that interested users can use to prepare a device-specific break-even analysis. For this purpose, various cost and revenue data are discussed, which have to be compiled and processed within the clinic and entered into prepared spreadsheets.
Conclusion: The breakeven point analysis can be used to determine the profit/loss (point) for the (planned) operation of imaging devices such as PET/CT. Users from imaging clinics/practices and administration can adapt the calculation tool presented to their specific facility and thus use it as a basic document for both the planned procurement and the ongoing operational control of imaging devices in everyday clinical practice.
{"title":"[Breakeven Analysis for Imaging Devices: Basic Introduction with Presentation of a User-Friendly Tool for in-clinic Calculation Using PET/CT as an Example].","authors":"Claus Zippel, Christina Antke, Yuriko Mori, Antje Sombetzki, Gerald Antoch, Frederik L Giesel","doi":"10.1055/a-2036-7694","DOIUrl":"https://doi.org/10.1055/a-2036-7694","url":null,"abstract":"<p><strong>Background: </strong>Imaging devices such as PET/CT are becoming increasingly important in view of the growing range of innovative nuclear medicine diagnostic procedures. Since the procurement and commissioning as well as the ongoing operation of imaging devices leads to comparatively high costs, it is of great interest for clinics and practices to know the number of scans from which the (planned) device operation leads to a profit. In the following, we will introduce the breakeven point analysis and present a calculation tool that users in nuclear medicine clinics and practices can use in everyday operations using PET/CT as an example.</p><p><strong>Methods: </strong>In the breakeven point analysis, the intersection point is determined from which the organisation- or device-specific revenues exceed the total costs incurred for personnel, material resources, etc. For this purpose, the fixed and variable (planned) cost components for the procurement and operation of the device must be prepared on the cost side and the respective device-related (planned) revenue structure on the revenue side.</p><p><strong>Results: </strong>The authors present the break-even analysis method with the data processing required for this using the example of the planned procurement or ongoing operation of a PET/CT. In addition, a calculation tool was developed, that interested users can use to prepare a device-specific break-even analysis. For this purpose, various cost and revenue data are discussed, which have to be compiled and processed within the clinic and entered into prepared spreadsheets.</p><p><strong>Conclusion: </strong>The breakeven point analysis can be used to determine the profit/loss (point) for the (planned) operation of imaging devices such as PET/CT. Users from imaging clinics/practices and administration can adapt the calculation tool presented to their specific facility and thus use it as a basic document for both the planned procurement and the ongoing operational control of imaging devices in everyday clinical practice.</p>","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"62 3","pages":"185-191"},"PeriodicalIF":1.5,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9874524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Paulina Cegla, Marta Wojewodzka-Mirocha, Wioletta Chalewska, Marek Dedecjus
Prostate cancer (PCa) is the second most frequent cancer diagnosis made in men and the fifth leading cause of death worldwide [1]. Prostate-specific membrane antigen labeled with gallium 68 ([68Ga]GaPSMA-11) is a promising radiotracer frequently used in diagnostics of the patients with biochemical recurrence of PCa. PSMA’s expression in non-small cell lung cancer (NSCLC) ranks around 16 %, while tumor neovasculature expression is seen in 59% of tumor samples and is dependent on NSCLC histopathological type. The highest (71%) is seen in large cell carcinoma (LCC) and in squamous cell carcinoma (SCC) – 64%, while the lowest (45%) is noted in adenocarcinoma (AC) [2, 3]. A 77-year-old man with prostate adenocarcinoma, Gleason 7 (3 + 4), TNM T2bNxM0, during hormonotherapy and urothelial carcinoma (T1bNxM0) during BCG therapy, was referred to [68Ga]GaPSMA-11 PET/CT study due to biochemical recurrence (total prostate specific antigen (t-PSA) 0.449 ng/ml). A cystoscopy performed one week before PET/CT examination was clear. The [68Ga]Ga-PSMA-11 showed an increased focal PSMA ligand uptake at the right side of the small pelvis (SUVmaxlbm up to 9.2, ▶ Fig. 1A), lump in segment 6 of the right lung (SUVmaxlbm up to 2.4, ▶ Fig. 1B) and area of parenchyma consolidation in segment 10 of the right lung (SUVmaxlbm up to 2.6, ▶ Fig. 1C). Moreover, [68Ga]Ga-PSMA-11 also revealed areas of pathological osteosclerotic remodeling in both hip bones and in both pubic bones without increased PSMA uptake. Patient underwent a resection of a lump (segment 6) in the right lung which revealed planoepitheliale lung cancer G3, pT1R0L1V1. Three months after resection, patient was referred to [18F]FDG PET/CT study which revealed (shown earlier in [68Ga]Ga-PSMA-11) tumor in segment 10 of the right lung (50 × 38 mm, SUVmaxlbm up to 12.3, ▶ Fig. 1D), branch of the diaphragm lymph node (18 × 20mm, SUVmaxlbm up to 5.8) and metastatic lesion in III right rib. Other changes in bones did not show any pathological uptake. Patient because of the comorbidities, age and extension of the disease was treated with palliative radiotherapy of the lung. A 69-year-old man t-PSA level 2.47 [ng/ mL], after prostatectomy followed by radiotherapy of regional lymph nodes and complementary hormonotherapy in 2007, currently under palliative hormonotherapy underwent [68Ga]Ga-PSMA-11 PET/CT study because of biochemical recurrence. The scan revealed a focal PSMA ligand uptake in the small pelvis (SUVmaxlbm up to 3.6), in enlarged right hilar lymph node SUVmaxlbm up to 2.7 (▶ Fig. 2A) and a soft-tissue lesion in left lung lower lobe (▶ Fig. 2B) with SUVmaxlbm up to 2.0. Patient a few months after [68Ga]Ga-PSMA11 PET/CT underwent a computed tomography (CT) examination of a thorax which showed right upper lobe mass extending round the main bronchus and involving hilar lymph nodes (▶ Fig. 2C). The soft-tissue lesion in the left lung lower lobe was less consolidated and more irregular in shape with a small cavity,
{"title":"[68Ga]Ga-PSMA-11 uptake in planepitheliale lung cancer: a pitfall in prostate cancer imaging.","authors":"Paulina Cegla, Marta Wojewodzka-Mirocha, Wioletta Chalewska, Marek Dedecjus","doi":"10.1055/a-2000-5589","DOIUrl":"https://doi.org/10.1055/a-2000-5589","url":null,"abstract":"Prostate cancer (PCa) is the second most frequent cancer diagnosis made in men and the fifth leading cause of death worldwide [1]. Prostate-specific membrane antigen labeled with gallium 68 ([68Ga]GaPSMA-11) is a promising radiotracer frequently used in diagnostics of the patients with biochemical recurrence of PCa. PSMA’s expression in non-small cell lung cancer (NSCLC) ranks around 16 %, while tumor neovasculature expression is seen in 59% of tumor samples and is dependent on NSCLC histopathological type. The highest (71%) is seen in large cell carcinoma (LCC) and in squamous cell carcinoma (SCC) – 64%, while the lowest (45%) is noted in adenocarcinoma (AC) [2, 3]. A 77-year-old man with prostate adenocarcinoma, Gleason 7 (3 + 4), TNM T2bNxM0, during hormonotherapy and urothelial carcinoma (T1bNxM0) during BCG therapy, was referred to [68Ga]GaPSMA-11 PET/CT study due to biochemical recurrence (total prostate specific antigen (t-PSA) 0.449 ng/ml). A cystoscopy performed one week before PET/CT examination was clear. The [68Ga]Ga-PSMA-11 showed an increased focal PSMA ligand uptake at the right side of the small pelvis (SUVmaxlbm up to 9.2, ▶ Fig. 1A), lump in segment 6 of the right lung (SUVmaxlbm up to 2.4, ▶ Fig. 1B) and area of parenchyma consolidation in segment 10 of the right lung (SUVmaxlbm up to 2.6, ▶ Fig. 1C). Moreover, [68Ga]Ga-PSMA-11 also revealed areas of pathological osteosclerotic remodeling in both hip bones and in both pubic bones without increased PSMA uptake. Patient underwent a resection of a lump (segment 6) in the right lung which revealed planoepitheliale lung cancer G3, pT1R0L1V1. Three months after resection, patient was referred to [18F]FDG PET/CT study which revealed (shown earlier in [68Ga]Ga-PSMA-11) tumor in segment 10 of the right lung (50 × 38 mm, SUVmaxlbm up to 12.3, ▶ Fig. 1D), branch of the diaphragm lymph node (18 × 20mm, SUVmaxlbm up to 5.8) and metastatic lesion in III right rib. Other changes in bones did not show any pathological uptake. Patient because of the comorbidities, age and extension of the disease was treated with palliative radiotherapy of the lung. A 69-year-old man t-PSA level 2.47 [ng/ mL], after prostatectomy followed by radiotherapy of regional lymph nodes and complementary hormonotherapy in 2007, currently under palliative hormonotherapy underwent [68Ga]Ga-PSMA-11 PET/CT study because of biochemical recurrence. The scan revealed a focal PSMA ligand uptake in the small pelvis (SUVmaxlbm up to 3.6), in enlarged right hilar lymph node SUVmaxlbm up to 2.7 (▶ Fig. 2A) and a soft-tissue lesion in left lung lower lobe (▶ Fig. 2B) with SUVmaxlbm up to 2.0. Patient a few months after [68Ga]Ga-PSMA11 PET/CT underwent a computed tomography (CT) examination of a thorax which showed right upper lobe mass extending round the main bronchus and involving hilar lymph nodes (▶ Fig. 2C). The soft-tissue lesion in the left lung lower lobe was less consolidated and more irregular in shape with a small cavity,","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"62 3","pages":"220-221"},"PeriodicalIF":1.5,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9558323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Merhnoosh Karimipourfard, Sedigheh Sina, Fereshteh Khodadai Shoshtari, Mehrosadat Alavi
{"title":"Correction: Synthesis of Prospective Multiple Time Points F-18 FDG PET Images from a Single Scan Using a Supervised Generative Adversarial Network.","authors":"Merhnoosh Karimipourfard, Sedigheh Sina, Fereshteh Khodadai Shoshtari, Mehrosadat Alavi","doi":"10.1055/a-2095-2016","DOIUrl":"https://doi.org/10.1055/a-2095-2016","url":null,"abstract":"","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"62 2","pages":"e1"},"PeriodicalIF":1.5,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9577464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yasemin Aylin Sahin, Friederike Eilsberger, Eric Einspänner, Johannes Kunz, Sarah Spreckelmeyer, Markus Luster, Winfried Brenner, Benjamin Kläsner, Adrien Holzgreve
Aim: In various medical societies, dedicated young talent sections provide an important basis for promoting young members. However, the German Society of Nuclear Medicine (DGN) had not yet implemented such a section. Therefore, the aim of this work was to assess the opinion of nuclear medicine professionals in Germany on establishing a young talent section within the DGN ("Young DGN").
Methods: An initiative group of young DGN members developed a survey questionnaire comprising 18 questions. The questionnaire was initially sent as a PDF to the members of the DGN University Committee (Hochschulausschuss) by e-mail on 10/12/2021. As an online survey, the questionnaire was then emailed at four additional time points between 12/23/2021 and 3/18/2022 via the DGN eBrief and on 2/23/2022 to the members of the mailing list of the Berufsverband Deutscher Nuklearmediziner (BDN).
Results: The survey closed on 3/31/2022 with 111 responses (n=104 online surveys, n=7 PDFs). The median age of participants was 32.5 years (range, 20-80). 86% of participants indicated that they were interested in a Young DGN section, of which 67% were willing to participate. 79% indicated that nuclear medicine was an exciting field for them. 96% expressed interest in additional education offers and 60% in the establishment of a mentoring program. 75% believed that Young DGN would improve the visibility of the specialty.
Conclusion: The survey results indicate strong support for the establishment of a young talent section within the DGN among nuclear medicine professionals in Germany. A large proportion of those who participated in the survey would envision active involvement. There was a particular consensus on the desire to expand the range of education and training activities.
目的:在各个医学学会中,专门的青年人才部门为青年会员的提升提供了重要的基础。然而,德国核医学学会(DGN)尚未执行这一节。因此,这项工作的目的是评估德国核医学专业人员对在DGN内建立年轻人才部门(“年轻DGN”)的意见。方法:一个由年轻DGN成员组成的倡议小组开发了一份包括18个问题的调查问卷。问卷最初于2021年12月10日以PDF格式通过电子邮件发送给DGN大学委员会(Hochschulausschuss)的成员。作为一项在线调查,问卷随后在2021年12月23日至2022年3月18日之间的四个额外时间点通过DGN eBrief和2022年2月23日通过电子邮件发送给Berufsverband Deutscher Nuklearmediziner (BDN)邮件列表的成员。结果:该调查于2022年3月31日结束,共有111份回复(n=104份在线调查,n=7份pdf)。参与者的中位年龄为32.5岁(范围20-80岁)。86%的参与者表示他们对年轻的DGN部分感兴趣,其中67%的人愿意参加。79%的人表示核医学对他们来说是一个令人兴奋的领域。96%的人表示有兴趣获得额外的教育机会,60%的人希望建立一个指导计划。75%的人认为年轻的DGN会提高该专业的知名度。结论:调查结果表明,德国核医学专业人员强烈支持在DGN内建立青年人才部门。很大一部分参与调查的人会设想积极参与。对于希望扩大教育和培训活动的范围,大家达成了特别的协商一致意见。
{"title":"[Is there an unmet need to establish a young talent section \"Young DGN\" within the German Society of Nuclear Medicine (DGN)? - Results of a 2021/2022 web-based survey among German Nuclear Medicine professionals].","authors":"Yasemin Aylin Sahin, Friederike Eilsberger, Eric Einspänner, Johannes Kunz, Sarah Spreckelmeyer, Markus Luster, Winfried Brenner, Benjamin Kläsner, Adrien Holzgreve","doi":"10.1055/a-1984-8116","DOIUrl":"https://doi.org/10.1055/a-1984-8116","url":null,"abstract":"<p><strong>Aim: </strong>In various medical societies, dedicated young talent sections provide an important basis for promoting young members. However, the German Society of Nuclear Medicine (DGN) had not yet implemented such a section. Therefore, the aim of this work was to assess the opinion of nuclear medicine professionals in Germany on establishing a young talent section within the DGN (\"Young DGN\").</p><p><strong>Methods: </strong>An initiative group of young DGN members developed a survey questionnaire comprising 18 questions. The questionnaire was initially sent as a PDF to the members of the DGN University Committee (<i>Hochschulausschuss</i>) by e-mail on 10/12/2021. As an online survey, the questionnaire was then emailed at four additional time points between 12/23/2021 and 3/18/2022 via the <i>DGN eBrief</i> and on 2/23/2022 to the members of the mailing list of the <i>Berufsverband Deutscher Nuklearmediziner</i> (BDN).</p><p><strong>Results: </strong>The survey closed on 3/31/2022 with 111 responses (n=104 online surveys, n=7 PDFs). The median age of participants was 32.5 years (range, 20-80). 86% of participants indicated that they were interested in a Young DGN section, of which 67% were willing to participate. 79% indicated that nuclear medicine was an exciting field for them. 96% expressed interest in additional education offers and 60% in the establishment of a mentoring program. 75% believed that Young DGN would improve the visibility of the specialty.</p><p><strong>Conclusion: </strong>The survey results indicate strong support for the establishment of a young talent section within the DGN among nuclear medicine professionals in Germany. A large proportion of those who participated in the survey would envision active involvement. There was a particular consensus on the desire to expand the range of education and training activities.</p>","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"62 2","pages":"55-60"},"PeriodicalIF":1.5,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9586094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-04-01Epub Date: 2023-03-06DOI: 10.1055/a-2026-0784
Merhnoosh Karimipourfard, Sedigheh Sina, Fereshteh Khodadai Shoshtari, Mehrosadat Alavi
The cumulative activity map estimation are essential tools for patient specific dosimetry with high accuracy, which is estimated using biokinetic models instead of patient dynamic data or the number of static PET scans, owing to economical and time-consuming points of view. In the era of deep learning applications in medicine, the pix-to-pix (p2 p) GAN neural networks play a significant role in image translation between imaging modalities. In this pilot study, we extended the p2 p GAN networks to generate PET images of patients at different times according to a 60 min scan time after the injection of F-18 FDG. In this regard, the study was conducted in two sections: phantom and patient studies. In the phantom study section, the SSIM, PSNR, and MSE metric results of the generated images varied from 0.98-0.99, 31-34 and 1-2 respectively and the fine-tuned Resnet-50 network classified the different timing images with high performance. In the patient study, these values varied from 0.88-0.93, 36-41 and 1.7-2.2, respectively and the classification network classified the generated images in the true group with high accuracy. The results of phantom studies showed high values of evaluation metrics owing to ideal image quality conditions. However, in the patient study, promising results were achieved which showed that the image quality and training data number affected the network performance. This study aims to assess the feasibility of p2 p GAN network application for different timing image generation.
累积活动图估计是高精度患者特定剂量学的重要工具,由于经济和耗时的观点,它使用生物动力学模型而不是患者动态数据或静态PET扫描次数来估计。在医学深度学习应用的时代,像素到像素(p2 p) GAN神经网络在成像模式之间的图像转换中发挥着重要作用。在这项初步研究中,我们扩展了p2 p GAN网络,根据注射F-18 FDG后60分钟的扫描时间,生成患者在不同时间的PET图像。在这方面,研究分为两个部分进行:幻影和患者研究。在幻影研究部分,生成图像的SSIM、PSNR和MSE度量结果分别为0.98-0.99、31-34和1-2,微调后的Resnet-50网络对不同时序图像进行了高性能分类。在患者研究中,这些值分别为0.88-0.93、36-41和1.7-2.2,分类网络对真实组生成的图像进行了较高的分类准确率。幻影研究结果表明,由于理想的图像质量条件,评估指标具有很高的价值。然而,在患者研究中,取得了令人鼓舞的结果,表明图像质量和训练数据数量会影响网络性能。本研究旨在评估p2 p GAN网络应用于不同时序图像生成的可行性。
{"title":"Synthesis of Prospective Multiple Time Points F-18 FDG PET Images from a Single Scan Using a Supervised Generative Adversarial Network.","authors":"Merhnoosh Karimipourfard, Sedigheh Sina, Fereshteh Khodadai Shoshtari, Mehrosadat Alavi","doi":"10.1055/a-2026-0784","DOIUrl":"10.1055/a-2026-0784","url":null,"abstract":"<p><p>The cumulative activity map estimation are essential tools for patient specific dosimetry with high accuracy, which is estimated using biokinetic models instead of patient dynamic data or the number of static PET scans, owing to economical and time-consuming points of view. In the era of deep learning applications in medicine, the pix-to-pix (p2 p) GAN neural networks play a significant role in image translation between imaging modalities. In this pilot study, we extended the p2 p GAN networks to generate PET images of patients at different times according to a 60 min scan time after the injection of F-18 FDG. In this regard, the study was conducted in two sections: phantom and patient studies. In the phantom study section, the SSIM, PSNR, and MSE metric results of the generated images varied from 0.98-0.99, 31-34 and 1-2 respectively and the fine-tuned Resnet-50 network classified the different timing images with high performance. In the patient study, these values varied from 0.88-0.93, 36-41 and 1.7-2.2, respectively and the classification network classified the generated images in the true group with high accuracy. The results of phantom studies showed high values of evaluation metrics owing to ideal image quality conditions. However, in the patient study, promising results were achieved which showed that the image quality and training data number affected the network performance. This study aims to assess the feasibility of p2 p GAN network application for different timing image generation.</p>","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"62 2","pages":"61-72"},"PeriodicalIF":1.2,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9947815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tina Nazerani-Zemann, Susanne Stanzel, Christian Gstettner, Reingard Maria Aigner, Birgit Pernthaler
More prevalent in women than men, Antisynthetase Syndrome is a rare and poorly defined autoimmune disease associated with interstitial lung disease, polymyositis, and dermatomyositis. In addition to various diagnostic tools, imaging modalities are needed in certain situations. A 42-year-old woman with Anti-Jo-1-positive Antisynthetase Syndrome presented with thoracic muscular pain. She underwent whole-body Fluorodeoxyglucose positron emission tomography/computed tomography (F18-FDG PET/CT) to evaluate the total extent of the muscles affected. Depicting symptomatic symmetric myositis of the intercostal muscles, F18-FDG PET/CT additionally revealed unusually extensive fasciitis of the lower extremities.
{"title":"F18-FDG PET/CT in a patient with Antisynthetase Syndrome.","authors":"Tina Nazerani-Zemann, Susanne Stanzel, Christian Gstettner, Reingard Maria Aigner, Birgit Pernthaler","doi":"10.1055/a-1996-0157","DOIUrl":"https://doi.org/10.1055/a-1996-0157","url":null,"abstract":"<p><p>More prevalent in women than men, Antisynthetase Syndrome is a rare and poorly defined autoimmune disease associated with interstitial lung disease, polymyositis, and dermatomyositis. In addition to various diagnostic tools, imaging modalities are needed in certain situations. A 42-year-old woman with Anti-Jo-1-positive Antisynthetase Syndrome presented with thoracic muscular pain. She underwent whole-body Fluorodeoxyglucose positron emission tomography/computed tomography (F18-FDG PET/CT) to evaluate the total extent of the muscles affected. Depicting symptomatic symmetric myositis of the intercostal muscles, F18-FDG PET/CT additionally revealed unusually extensive fasciitis of the lower extremities.</p>","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"62 2","pages":"73-74"},"PeriodicalIF":1.5,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/74/8b/10-1055-a-1996-0157.PMC10063341.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9225282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-04-01Epub Date: 2023-03-30DOI: 10.1055/a-1998-8402
Friederike Eilsberger, Constantin Lapa, Benjamin Kläsner, Michael Andreas Schäfers, Markus Luster
{"title":"[Hand in hand - the future of SPECT and PET imaging].","authors":"Friederike Eilsberger, Constantin Lapa, Benjamin Kläsner, Michael Andreas Schäfers, Markus Luster","doi":"10.1055/a-1998-8402","DOIUrl":"10.1055/a-1998-8402","url":null,"abstract":"","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"62 2","pages":"52-53"},"PeriodicalIF":1.2,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9352942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
L. Flegar, S. Thoduka, D. Librizzi, M. Luster, A. Zacharis, H. Heers, N. Eisenmenger, H. Ahmadzadehfar, M. Eiber, W. Weber, C. Groeben, J. Huber
Ziel/Aim To investigate the adoption and current trends of Lutetium-177 PSMA radioligand therapy (RLT) for metastatic castration-resistant prostate cancer (mCRPC) in Germany.
{"title":"Lutetium-177 PSMA radioligand therapy for metastatic castration resistant prostate cancer in Germany: population-based data with multicenter validation from 2016 to 2020","authors":"L. Flegar, S. Thoduka, D. Librizzi, M. Luster, A. Zacharis, H. Heers, N. Eisenmenger, H. Ahmadzadehfar, M. Eiber, W. Weber, C. Groeben, J. Huber","doi":"10.1055/s-0043-1766222","DOIUrl":"https://doi.org/10.1055/s-0043-1766222","url":null,"abstract":"Ziel/Aim To investigate the adoption and current trends of Lutetium-177 PSMA radioligand therapy (RLT) for metastatic castration-resistant prostate cancer (mCRPC) in Germany.","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"92 1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135419773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
T. Demmert, I. Maric, K. Pomykala, K. Lückerath, J. Siveke, B. Schaarschmidt, R. Hamacher, L. Kessler, N. Hirmas, K. Pabst, T. Bartel, K. Herrmann, W. Fendler
Ziel/Aim The global SARS-CoV-2 vaccination campaign brought attention to a recent pitfall in tumor staging by PET/CT. Several publications reported a non-specific F-18-FDG tracer uptake in axillary lymph nodes after COVID-19 vaccination. Ga-68-FAPI PET/CT is a new oncologic imaging tool that may overcome this limitation.
{"title":"Novel Ga-68-FAPI PET/CT offers oncologic staging without COVID-19 vaccine-related pitfalls","authors":"T. Demmert, I. Maric, K. Pomykala, K. Lückerath, J. Siveke, B. Schaarschmidt, R. Hamacher, L. Kessler, N. Hirmas, K. Pabst, T. Bartel, K. Herrmann, W. Fendler","doi":"10.1055/s-0043-1766277","DOIUrl":"https://doi.org/10.1055/s-0043-1766277","url":null,"abstract":"Ziel/Aim The global SARS-CoV-2 vaccination campaign brought attention to a recent pitfall in tumor staging by PET/CT. Several publications reported a non-specific F-18-FDG tracer uptake in axillary lymph nodes after COVID-19 vaccination. Ga-68-FAPI PET/CT is a new oncologic imaging tool that may overcome this limitation.","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"139 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135419774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
B. Hooshyar Yousefi, B. C. Uzuegbunam, W. Paslawski, G. B. Kotipalli, M. Luster, D. Librizzi, W. Weber, P. Svenningsson, T. Arzberger
Ziel/Aim The deposition of α-synuclein fibrils (α-syn) is a major feature that unites a group of neurodegenerative diseases collectively known as the synucleinopathies. Presently, the in vivo detection of this biomarker is not possible due to lack of suitable radiotracers. Scientists from academics and industry are interested to develop radiotracers for the early diagnosis of α-synucleinopathies. Disarylbisthiazoles (DABTAs) based ligands have been showing high affinity towards α-syn and excellent selectivity over tau and Aβ aggregates. The aim of this work is characterization of the radiotracers within competition binding assays, autoradiography and pharmacokinetics (PK) study to confirm their high binding affinity and optimized pharmacokinetics and utilize them as a promising α-syn PET tracer.
{"title":"Selective α-Synuclein PET Radiotracer Development- Characterization","authors":"B. Hooshyar Yousefi, B. C. Uzuegbunam, W. Paslawski, G. B. Kotipalli, M. Luster, D. Librizzi, W. Weber, P. Svenningsson, T. Arzberger","doi":"10.1055/s-0043-1766158","DOIUrl":"https://doi.org/10.1055/s-0043-1766158","url":null,"abstract":"Ziel/Aim The deposition of α-synuclein fibrils (α-syn) is a major feature that unites a group of neurodegenerative diseases collectively known as the synucleinopathies. Presently, the in vivo detection of this biomarker is not possible due to lack of suitable radiotracers. Scientists from academics and industry are interested to develop radiotracers for the early diagnosis of α-synucleinopathies. Disarylbisthiazoles (DABTAs) based ligands have been showing high affinity towards α-syn and excellent selectivity over tau and Aβ aggregates. The aim of this work is characterization of the radiotracers within competition binding assays, autoradiography and pharmacokinetics (PK) study to confirm their high binding affinity and optimized pharmacokinetics and utilize them as a promising α-syn PET tracer.","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"106 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135419775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}